Aclaris Therapeutics ACRS Income Statement (2014-2026)

NASDAQ ACRS
$5.99 +0.04 (+0.59%)
As of: Sep 4, 2026 · 11:49 AM EDT
Reported Financials

Aclaris Therapeutics Quarterly Income Statement

Periods 48 quarters
Latest Jun 2026

Aclaris Therapeutics reported revenue of $1.63M and net income of -$21.83M for the quarter ended Jun 2026, down 8.3% year over year. This income statement covers 48 quarters of results from Sep 2014 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
61.23M61.23M61.74M66.67M66.68M66.69M67.21M70.77M70.82M70.89M71.25M71.33M71.42M77.30M108.27M108.33M108.34M120.50M139.65M139.82M
Revenue & cost
Revenue
1.66M1.50M1.45M1.53M19.02M7.75M2.53M1.87M9.28M17.57M2.40M2.77M4.35M9.21M1.46M1.78M3.30M1.29M2.00M1.63M
Gross Profit
0.56M0.35M0.30M0.46M18.09M6.88M1.72M0.83M8.43M16.84M1.59M2.14M3.69M8.51M0.95M1.26M2.76M0.76M1.60M1.41M
Operating items
Amortization - Intangibles
Research & DevelopmentR&D
13.98M14.10M14.31M18.78M23.66M21.07M22.59M25.27M23.88M26.65M9.85M8.76M5.96M9.03M11.58M11.45M13.03M16.58M15.66M18.07M
Selling, General & AdministrativeSG&A
5.98M6.94M6.10M6.08M5.81M7.15M8.79M8.32M7.09M8.21M6.84M4.75M5.65M4.95M6.14M5.39M4.87M5.58M6.74M6.05M
Other Operating ExpensesOther Opex
2.00M3.35M-0.04M-2.33M10.42M8.61M1.07M0.09M9.89M-13.24M4.64M2.11M3.21M94.91M1.82M3.35M2.55M1.87M1.79M1.75M
Operating ExpensesOpex
21.95M24.39M20.36M22.52M39.89M36.83M32.45M33.68M40.86M21.62M21.33M15.62M14.82M108.89M19.54M20.18M20.45M24.03M24.19M25.87M
Operating IncomeOp. Inc
-20.30M-22.89M-18.91M-20.99M-20.87M-29.08M-29.92M-31.82M-31.58M-4.05M-18.93M-12.85M-10.47M-99.67M-18.08M-18.41M-17.15M-22.73M-22.19M-24.24M
EBIT
-20.30M-22.89M-18.91M-20.99M-20.87M-29.08M-29.92M-31.82M-31.58M-4.05M-18.93M-12.85M-10.47M-99.67M-18.08M-18.41M-17.15M-22.73M-22.19M-24.24M
Non-operating items
Interest & Investment IncomeInt & Inv Inc
0.01M-0.22M-0.75M-0.35M-0.14M0.57M0.54M-0.76M2.32M2.19M1.99M1.87M1.99M2.10M2.17M2.02M1.82M1.63M1.51M1.76M
Other Non Operating IncomeOther Non Op Inc.
-0.85M0.09M0.12M0.46M0.92M1.44M1.76M2.25M2.32M2.19M1.99M1.87M
Non Operating IncomeNon Op. Inc.
2.32M2.19M1.99M1.87M2.88M3.12M3.00M2.98M2.54M2.94M2.37M2.73M
Net income details
EBT
-20.29M-23.12M-19.66M-21.35M-21.01M-28.51M-29.38M-32.57M-29.26M-1.86M-16.94M-10.99M-8.48M-97.57M-15.92M-16.39M-15.33M-21.10M-20.68M-22.48M
Profit After TaxPAT
-21.15M-22.93M-18.79M-20.53M-20.09M-27.07M-28.16M-29.57M-29.28M-1.26M-16.94M-10.99M-7.59M-96.55M-15.09M-15.43M-14.61M-19.80M-19.82M-21.83M
Income from Continuing OperationsIncome (Continuing)
-20.29M-23.12M-19.66M-21.35M-21.01M-28.51M-29.38M-32.57M-29.26M-1.86M-16.94M-10.99M-8.48M-97.57M-15.92M-16.39M-15.33M-21.10M-20.68M-22.48M
Income from Discontinued OperationsIncome (Discontinued)
Consolidated Net IncomeConsol Net Inc.
-20.29M-23.12M-19.66M-21.35M-21.01M-28.51M-29.38M-32.57M-29.26M-1.86M-16.94M-10.99M-8.48M-97.57M-15.92M-16.39M-15.33M-21.10M-20.68M-22.48M
Income towards Parent CompanyParent Net Inc
-20.29M-23.12M-19.66M-21.35M-21.01M-28.51M-29.38M-32.57M-29.26M-1.86M-16.94M-10.99M-8.48M-97.57M-15.92M-16.39M-15.33M-21.10M-20.68M-22.48M
Preferred Dividend PaymentsPref Dividends
Net Income towards Common StockholdersNet Income
-20.29M-23.12M-19.66M-21.35M-21.01M-28.51M-29.38M-32.57M-29.26M-1.86M-16.94M-10.99M-8.48M-97.57M-15.92M-16.39M-15.33M-21.10M-20.68M-22.48M
Additional items
EPS (Basic)
-0.33-0.41-0.32-0.32-0.32-0.44-0.44-0.46-0.41-0.03-0.24-0.15-0.12-1.26-0.13-0.13-0.13-0.17-0.16-0.16
EPS (Diluted)
-0.33-0.41-0.32-0.32-0.32-0.44-0.44-0.46-0.41-0.03-0.24-0.15-0.12-1.26-0.13-0.13-0.13-0.17-0.16-0.16
Shares Outstanding
61.22M56.73M61.43M65.99M66.68M65.21M66.87M70.63M70.81M69.81M71.07M71.29M71.38M77.30M122.39M122.58M122.62M122.56M128.81M142.74M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
61.22M56.73M61.43M65.99M66.68M65.21M66.87M70.63M70.81M69.81M71.07M71.29M71.38M77.30M122.39M122.58M122.62M122.56M128.81M142.74M
EBITDA
-20.30M-22.89M-18.91M-20.99M-20.87M-29.08M-29.92M-31.82M-31.58M-4.05M-18.93M-12.85M-10.47M-99.67M-18.08M-18.41M-17.15M-22.73M-22.19M-24.24M